4.6 • 654 Ratings
🗓️ 15 June 2023
⏱️ 150 minutes
🧾️ Download transcript
Click on a timestamp to play from that location
0:00.0 | Welcome to the Commune podcast. My name is Jeff Krasno. Today on the show, I welcome Dr. Dave Rabin. |
0:15.8 | Dave is a neuroscientist and board-certified psychiatrist with a focus on integration therapy and psychedelic |
0:23.9 | assisted psychotherapy. He specializes in treatment-resistant mental illnesses, including depression, |
0:31.2 | anxiety, PTSD, and insomnia. Obviously a useful fellow in these times. |
0:39.3 | Dave and I touch on the many aspects of the current mental health epidemic. |
0:43.3 | Specifically, we discuss the potential benefits and mechanisms of ketamine-assisted therapy. |
0:50.3 | Historically, ketamine has been considered an anesthetic used to sedate both humans and famously horses, |
0:58.0 | and it's been widely used for recreational purposes. But now, it's also the subject of an enormous amount of interest as a fast-acting treatment for depression and other serious mental health |
1:12.7 | conditions. A little history. Ketamine was first approved as an anesthetic in 1970, but using it to |
1:21.1 | address psychiatric conditions has been considered, quote-unquote, off-label. This means it's legal for a doctor to prescribe, but it's not |
1:30.1 | approved by the FDA for that particular indication. However, this is now changing. In 2019, the FDA |
1:38.6 | approved S-Kedamine, a nasal spray that is marketed as spravato for treatment-resistant depression and acute suicidal thinking. |
1:48.3 | Oketamine administration, along with other protocols involving a combination of psychedelics and talk therapy, |
1:55.0 | have gained tremendous momentum in recent years, particularly given new studies that have questioned the efficacy of |
2:03.7 | popular antidepressants, such as SSRIs. Given the lack of statistically significant correlation |
2:11.1 | between low serotonin levels and depression, Dr. Dave and I discuss some of the best clinical |
2:17.3 | research on the use of psychedelic assisted therapy. |
2:22.3 | In our conversation, we discuss exposure therapy, neuroplasticity, and epigenetics, |
2:26.9 | and the link between trauma and depression. |
2:30.4 | And we take a deep dive into the history of the biochemical theory of depression and its focus on serotonin. |
2:38.6 | If you want to learn more on this fascinating topic, consider taking Dr. Dave Raven's new Commune course on Neuroplasticity, titled Rewire Your Brain. |
2:49.5 | To sign up for the first four days for free, |
... |
Please login to see the full transcript.
Disclaimer: The podcast and artwork embedded on this page are from Commune Media, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of Commune Media and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2025.